TY - JOUR
T1 - Comparison of different CD71 monoclonal antibodies for enrichment of fetal cells from maternal blood
AU - Prieto, Belén
AU - Cándenas, Mercedes
AU - Ladenson, Jack H.
AU - Álvarez, Francisco V.
N1 - Funding Information:
This project was supported by the Fondo de Investigación Sanitaria (98/1530), Fundación para el Fomento en Asturias de la Investigación Científica y Aplicada (PB-SAL99-02) and Fun-dación Inocente Inocente. We thank all the women who participated in this study, and those physicians who collaborated in sending us maternal blood samples. We also thank Rosalía García for her excellent technical work, as well as Jitka Olan-der for critical comments on the manuscript. The antibodies used in this paper are at this time under option for exclusive license through the Washington University Center of Technology Management.
PY - 2002
Y1 - 2002
N2 - Different approaches have been proposed for the enrichment of fetal nucleated red blood cells. (NRBC) from maternal blood as an alternative way to obtain fetal tissue for non-invasive prenatal diagnosis. The main purpose of this study was to compare two of our monoclonal antibodies (2E11.3 and 2B7.4 mAbs) with the most widely used commercial anti-CD71 mAb, in terms of their ability to isolate NRBC from maternal blood by magnetic activated cell sorting (MACS). Peripheral blood samples were obtained from 60 pregnant women at a mean gestational age of 16 weeks (range: 10-19 weeks). The number of NRBC isolated by our antibodies (median: 68, range: 0-2102) was significantly higher than that obtained by the commercial antibody (median: 38, range: 0-2165) in the same samples. However, in the final preparations, contamination by maternal nucleated blood cells was lower when the commercial antibody was used. Since fetal NRBC are rare in maternal blood, the improved NRBC recovery achieved by our non-commercial antibodies should facilitate the non-invasive detection of fetal aneuploidies in maternal blood.
AB - Different approaches have been proposed for the enrichment of fetal nucleated red blood cells. (NRBC) from maternal blood as an alternative way to obtain fetal tissue for non-invasive prenatal diagnosis. The main purpose of this study was to compare two of our monoclonal antibodies (2E11.3 and 2B7.4 mAbs) with the most widely used commercial anti-CD71 mAb, in terms of their ability to isolate NRBC from maternal blood by magnetic activated cell sorting (MACS). Peripheral blood samples were obtained from 60 pregnant women at a mean gestational age of 16 weeks (range: 10-19 weeks). The number of NRBC isolated by our antibodies (median: 68, range: 0-2102) was significantly higher than that obtained by the commercial antibody (median: 38, range: 0-2165) in the same samples. However, in the final preparations, contamination by maternal nucleated blood cells was lower when the commercial antibody was used. Since fetal NRBC are rare in maternal blood, the improved NRBC recovery achieved by our non-commercial antibodies should facilitate the non-invasive detection of fetal aneuploidies in maternal blood.
KW - Density gradient
KW - Fluorescence in situ hybridization (FISH)
KW - Magnetic activated cell sorting (MACS)
KW - Monoclonal antibodies
KW - Nucleated erythrocytes
KW - Prenatal diagnosis
UR - http://www.scopus.com/inward/record.url?scp=0036207178&partnerID=8YFLogxK
U2 - 10.1515/CCLM.2002.022
DO - 10.1515/CCLM.2002.022
M3 - Article
C2 - 11939484
AN - SCOPUS:0036207178
SN - 1434-6621
VL - 40
SP - 126
EP - 131
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
IS - 2
ER -